English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsMankind pharma ipo

    Mankind Pharma Ipo

    Jump to
    • Why have MFs fallen in love with Mankind Pharma just a month since its listing?

      Why have MFs fallen in love with Mankind Pharma just a month since its listing?

      Put it down to the home advantage, or the company’s strong position in the Indian pharmaceuticals market.

    • NPPA fixes ceiling prices of 18 formulations and 23 new drugs

      NPPA fixes ceiling prices of 18 formulations and 23 new drugs

      As per the notification, the drug Isoniazid used for treating Myobacterium tuberculosis will have a ceiling price of Rs. 1.29 and Gliclazide ER and Metformin Hydrochloride (ER) tablets used by patients with type 2 diabetes will have a ceiling price of Rs. 10.03 for one tablet

    • Moneycontrol Daily: Your Essential 7

      Moneycontrol Daily: Your Essential 7

      A daily round-up of the most interesting articles to help jump-start the day.

    • Mankind Pharma IPO: After a giant leap by Mankind Pharma, should you too take a leap of faith?

      Mankind Pharma IPO: After a giant leap by Mankind Pharma, should you too take a leap of faith?

      Mankind Pharma IPO: The company is almost entirely focussed in India. The domestic market contributed 97.60 percent to the company's revenue from operations in FY22

    • Mankind Pharma IPO Day 2: Offer subscribed 87%, QIB portion fully booked

      Mankind Pharma IPO Day 2: Offer subscribed 87%, QIB portion fully booked

      Mankind Pharma IPO: The issue, which is an offer for sale, is expected to fetch the pharma company's shareholders Rs 4,326.36 crore at the upper end of the price band of Rs 1,026-1,080 a share

    • Mankind Pharma: IPO price, company financials; Here are 10 key things to know

      Mankind Pharma: IPO price, company financials; Here are 10 key things to know

      The biggest IPO of 2023 so far in terms of issue size - Mankind Pharma IPO - opened for subscription on April 25. The total fundraising would be Rs 4,110 cr at the lower price band. It has established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, etc. Here are the 10 key things you must know before applying for this IPO!

    • Mankind Pharma's Rs 4,326-cr public issue keeps analysts upbeat on local flavour

      Mankind Pharma's Rs 4,326-cr public issue keeps analysts upbeat on local flavour

      The company has priced the issue in the range of Rs 1,026-1,080 per share. It mobilised Rs 1,297.9 crore from a clutch of anchor investors including CPPIB, GIC, ADIA, Fidelity, Goldman Sachs and Blackrock

    • Mankind Pharma IPO: A pricey proposition on branded domestic pharma market

      Mankind Pharma IPO: A pricey proposition on branded domestic pharma market

      As the company is foraying into newer areas of therapies, particularly chronic, there could be execution hiccups.

    • Mankind Pharma IPO: Goldman Sachs, Blackrock, CPPIB, domestic MFs among anchor investors

      Mankind Pharma IPO: Goldman Sachs, Blackrock, CPPIB, domestic MFs among anchor investors

      Ahead of the IPO, Mankind Pharma mobilised Rs 1,297.9 crore from anchor investors. Total 77 investors have received shares via anchor book.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347